Skip to menu Skip to content Skip to footer

2021

Conference Publication

Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive after Treatment for Relapsed Follicular Lymphoma: Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study

Trotman, Judith, Presgrave, Peter, Carradice, Duncan P., Lenton, Douglas Stuart, Gandhi, Maher, Cochrane, Tara, Badoux, Xavier, NKhoma, Gloria, Butcher, Belinda, Fulham, Michael and Johnston, Anna (2021). Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive after Treatment for Relapsed Follicular Lymphoma: Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study. 63rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta Ga, Dec 11-14, 2021. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2021-146343

Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive after Treatment for Relapsed Follicular Lymphoma: Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study

2021

Journal Article

Event-Free and Overall Survival in over 6,000 Patients Treated with Frontline Immunochemotherapy for Follicular Lymphoma between 2002-2018: First Report from the International FLIPI24 Consortium

Maurer, Matthew J., Prochazka, Vit K, Flowers, Christopher R., Jakobsen, Lasse H., Villa, Diego, Weibull, Caroline, Cahn, Elliot J., Ghesquieres, Herve, Kridel, Robert, Gandhi, Maher, Cheah, Chan Yoon, Hawkes, Eliza, Seymour, John F., Freeman, Ciara L., Clausen, Michael Roost, Wahlin, Björn, Link, Brian K., Smedby, Karin Ekstroem, Sehn, Laurie H., Trněný, Marek, El-Galaly, Tarec Christoffer and Cerhan, James R. (2021). Event-Free and Overall Survival in over 6,000 Patients Treated with Frontline Immunochemotherapy for Follicular Lymphoma between 2002-2018: First Report from the International FLIPI24 Consortium. Blood, 138 (Supplement 1), 138. doi: 10.1182/blood-2021-145883

Event-Free and Overall Survival in over 6,000 Patients Treated with Frontline Immunochemotherapy for Follicular Lymphoma between 2002-2018: First Report from the International FLIPI24 Consortium

2021

Journal Article

Immunity reloaded: deconstruction of the PD-1 axis in B cell lymphomas

Bednarska, Karolina, Nath, Karthik, Nicol, William and Gandhi, Maher K. (2021). Immunity reloaded: deconstruction of the PD-1 axis in B cell lymphomas. Blood Reviews, 50 100832, 100832. doi: 10.1016/j.blre.2021.100832

Immunity reloaded: deconstruction of the PD-1 axis in B cell lymphomas

2021

Journal Article

Intratumoral T‐cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B‐cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R‐CHOP) chemoimmunotherapy

Shanavas, Mohamed, Law, Soi‐Cheng, Hertzberg, Mark, Hicks, Rodney J., Seymour, John F., Li, Zhixiu, Merida de Long, Lilia, Nath, Karthik, Sabdia, Muhammed B., Gunawardana, Jay, Gandhi, Maher K. and Keane, Colm (2021). Intratumoral T‐cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B‐cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R‐CHOP) chemoimmunotherapy. Clinical and Translational Immunology, 10 (11) e1351, e1351. doi: 10.1002/cti2.1351

Intratumoral T‐cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B‐cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R‐CHOP) chemoimmunotherapy

2021

Journal Article

Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic target

Gould, Clare, Lickiss, Jennifer, Kankanige, Yamuna, Yerneni, Satwica, Lade, Stephen, Gandhi, Maher K., Chin, Collin, Yannakou, Costas K., Villa, Diego, Slack, Graham W., Markham, John F., Tam, Constantine S., Nelson, Niles, Seymour, John F., Dickinson, Michael, Neeson, Paul J., Westerman, David and Blombery, Piers (2021). Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic target. British Journal of Haematology, 195 (1) bjh.17789, 113-118. doi: 10.1111/bjh.17789

Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic target

2021

Journal Article

Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphoma

Nath, Karthik, Law, Soi-Cheng, Sabdia, Muhammed B., Gunawardana, Jay, de Long, Lilia M., Sester, David, Shanavas, Mohamed, Tsang, Hennes, Tobin, Joshua W. D., Halliday, Sarah-Jane, Hernandez, Annette, Cross, Donna, Bird, Robert J., Jain, Sanjiv, Keane, Colm, Talaulikar, Dipti, Trotman, Judith, Law, Phillip and Gandhi, Maher K. (2021). Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphoma. Blood Advances, 5 (12), 2644-2649. doi: 10.1182/bloodadvances.2020004051

Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphoma

2021

Journal Article

Successful treatment of Epstein–Barr virus–associated primary central nervous system lymphoma due to post‐transplantation lymphoproliferative disorder, with ibrutinib and third‐party Epstein–Barr virus–specific T cells

Law, Soi C., Hoang, Thanh, O'Rourke, Kacey, Tobin, Joshua W. D., Gunawardana, Jay, Loo‐Oey, Dorothy, Bednarska, Karolina, Merida de Long, Lilia, Sabdia, Muhammed B., Hapgood, Greg, Blyth, Emily, Clancy, Leighton, Hennig, Stefanie, Keane, Colm and Gandhi, Maher K. (2021). Successful treatment of Epstein–Barr virus–associated primary central nervous system lymphoma due to post‐transplantation lymphoproliferative disorder, with ibrutinib and third‐party Epstein–Barr virus–specific T cells. American Journal of Transplantation, 21 (10) ajt.16628, 3465-3471. doi: 10.1111/ajt.16628

Successful treatment of Epstein–Barr virus–associated primary central nervous system lymphoma due to post‐transplantation lymphoproliferative disorder, with ibrutinib and third‐party Epstein–Barr virus–specific T cells

2021

Journal Article

Discordant solutions to discordant problems

Tobin, Joshua W. D. and Gandhi, Maher K. (2021). Discordant solutions to discordant problems. Blood, 137 (21), 2857-2858. doi: 10.1182/blood.2021011362

Discordant solutions to discordant problems

2021

Other Outputs

A cost-effectiveness analysis of front-line treatment strategies in early stage follicular lymphoma

Tobin, Joshua W.D., Crothers, Anna, Eric, Ti, Mollee, Peter, Gandhi, Maher K., Scuffham, Paul and Hapgood, Greg (2021). A cost-effectiveness analysis of front-line treatment strategies in early stage follicular lymphoma. doi: 10.1101/2021.03.24.21254220

A cost-effectiveness analysis of front-line treatment strategies in early stage follicular lymphoma

2021

Journal Article

EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity

Gandhi, Maher K., Hoang, Thanh, Law, Soi C., Brosda, Sandra, O'Rourke, Kacey, Tobin, Joshua W. D., Vari, Frank, Murigneux, Valentine, Fink, J. Lynn, Gunawardana, Jay, Gould, Clare M., Oey, Harald, Bednarska, Karolina, Delecluse, Susanne, Trappe, Ralf Ulrich, de Long, Lilia Merida, Sabdia, Muhammed Bilal, Bhagat, Govind, Hapgood, Greg, Blyth, Emily, Clancy, Leighton E., Wight, Joel, Hawkes, Eliza A., Rimsza, Lisa M., Maguire, Alanna, Bojarczuk, Kamil, Chapuy, Bjoern and Keane, Colm (2021). EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity. Blood, 137 (11), 1468-1477. doi: 10.1182/blood.2020008520

EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity

2021

Journal Article

Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience

Lewis, Katharine L., Chin, Collin K., Manos, Kate, Casey, John, Hamad, Nada, Crawford, Julie, Ho, Shir-Jing, Issa, Samar, Grigg, Andrew, Wood, Peter, Gandhi, Maher K., Do, Bryan, Nastoupil, Loretta, Hawkes, Eliza A. and Cheah, Chan Y. (2021). Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience. British Journal of Haematology, 192 (6) bjh.16946, 1049-1053. doi: 10.1111/bjh.16946

Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience

2021

Journal Article

Targeted treatment of follicular lymphoma

Nath, Karthik and Gandhi, Maher K. (2021). Targeted treatment of follicular lymphoma. Journal of Personalized Medicine, 11 (2) 152, 1-22. doi: 10.3390/jpm11020152

Targeted treatment of follicular lymphoma

2021

Journal Article

A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphoma

Tobin, Joshua W. D., Crothers, Anna, Ma, Ti Eric, Mollee, Peter, Gandhi, Maher K., Scuffham, Paul and Hapgood, Greg (2021). A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphoma. Leukemia and Lymphoma, 62 (14), 1-9. doi: 10.1080/10428194.2021.1957866

A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphoma

2021

Journal Article

Tumor microenvironment of follicular lymphoma

Nath, Karthik, Tsang, Hennes and Gandhi, Maher K. (2021). Tumor microenvironment of follicular lymphoma. Annals of Lymphoma, 5, 1-19. doi: 10.21037/aol-20-55

Tumor microenvironment of follicular lymphoma

2021

Book Chapter

Host genetic mutations and expression analyses in PTLD

Lees, Charlotte and Gandhi, Maher K. (2021). Host genetic mutations and expression analyses in PTLD. Post-transplant lymphoproliferative disorders. (pp. 39-50) edited by Vikas R. Dharnidharka, Michael Green, Steven A. Webber and Ralf Ulrich Trappe. Cham, Switzerland: Springer . doi: 10.1007/978-3-030-65403-0_4

Host genetic mutations and expression analyses in PTLD

2020

Journal Article

Increased lipid metabolism impairs NK cell function and mediates adaptation to the lymphoma environment

Kobayashi, Takumi, Lam, Pui Yeng, Jiang, Hui, Bednarska, Karolina, Gloury, Renee Elyse, Murigneux, Valentine, Tay, Joshua, Jacquelot, Nicolas, Li, Rui, Tuong, Zewen Kelvin, Leggatt, Graham, Gandhi, Maher K., Hill, Michelle M, Belz, Gabrielle T., Ngo, Shyuan, Kallies, Axel and Mattarollo, Stephen R. (2020). Increased lipid metabolism impairs NK cell function and mediates adaptation to the lymphoma environment. Blood, 136 (26), 3004-3017. doi: 10.1182/blood.2020005602

Increased lipid metabolism impairs NK cell function and mediates adaptation to the lymphoma environment

2020

Conference Publication

A cost-effectiveness analysis of front-line treatment strategies in early stage follicular lymphoma

Tobin, Joshua W.D., Hapgood, Greg, Gandhi, Maher K., Mollee, Peter, Ma, Ti, Crothers, Anna and Scuffham, Paul (2020). A cost-effectiveness analysis of front-line treatment strategies in early stage follicular lymphoma. 62nd ASH Annual Meeting and Exposition, Online, 5-8 December 2020. Washington, DC USA: American Society of Hematology. doi: 10.1182/blood-2020-138590

A cost-effectiveness analysis of front-line treatment strategies in early stage follicular lymphoma

2020

Conference Publication

Neoantigens are typically associated with intact HLA class I presentation in early-stage follicular lymphoma

Tsang, Hennes, Patch, Ann-Marie, Keane, Colm, Law, Soi C., Gunawardana, Jay, Blombery, Piers, Thompson, Ella R., Sabdia, Muhammed B., De Long, Lilia Merida, Belle, Clemence J., Nath, Karthik, Tobin, Joshua W.D., Kazakoff, Stephen H., Seymour, John F., MacManus, Michael and Gandhi, Maher K. (2020). Neoantigens are typically associated with intact HLA class I presentation in early-stage follicular lymphoma. 62nd ASH Annual Meeting and Exposition, Online, 5-8 December 2020. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2020-135954

Neoantigens are typically associated with intact HLA class I presentation in early-stage follicular lymphoma

2020

Journal Article

DA-EPOCH-R in Burkitt Lymphoma: Is it enough for high-risk disease?

Hertzberg, Mark, Joske, David J. L. and Gandhi, Maher K. (2020). DA-EPOCH-R in Burkitt Lymphoma: Is it enough for high-risk disease?. Journal of Clinical Oncology, 38 (31), 3722-3723. doi: 10.1200/jco.20.01850

DA-EPOCH-R in Burkitt Lymphoma: Is it enough for high-risk disease?

2020

Journal Article

Genetic aberrations of NLRC5 are associated with downregulated MHC‐I antigen presentation and impaired T‐cell immunity in follicular lymphoma

Gunawardana, Jay, Lee, Justina N., Bednarska, Karolina, Murigneux, Valentine, Long, Lilia Merida, Sabdia, Muhammed B., Birch, Simone, Tobin, Joshua W. D. and Gandhi, Maher K. (2020). Genetic aberrations of NLRC5 are associated with downregulated MHC‐I antigen presentation and impaired T‐cell immunity in follicular lymphoma. eJHaem, 1 (2) jha2.116, 517-526. doi: 10.1002/jha2.116

Genetic aberrations of NLRC5 are associated with downregulated MHC‐I antigen presentation and impaired T‐cell immunity in follicular lymphoma